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AR = attributable risk; ARR = absolute risk reduction; ARDS = acute respiratory distress syndrome; NNH = number needed to harm; NNT =
number needed to treat; OR = odds ratio; RR = relative risk; SE = standard error.
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Introduction
As an example, we shall refer to the findings of a prospective
cohort study conducted by Quasney and coworkers [1] of
402 adults admitted to the Memphis Methodist Healthcare
System with community-acquired pneumonia. That study
investigated the association between surfactant protein B
and acute respiratory distress syndrome (ARDS). Patients
were classified according to their thymine/cytosine (C/T)
gene coding, and patients with the C allele present (genotype
CC or CT) were compared with those with genotype TT. The
results are shown in Table 1.
The risk that an individual with the C allele present will
develop ARDS is the probability of such an individual
developing ARDS. In the study we can estimate this risk by
calculating the proportion of individuals with the C allele
present who develop ARDS (i.e. 11/219 = 0.050).
Relative risk
Relative risk (RR), or the risk ratio, is the ratio of the risk for
the disease in the group exposed to the factor, to that in the
unexposed group. For the data given in Table 1, if the
presence of the C allele is regarded as the risk factor, then
the RR for ARDS is estimated by the following:




Estimated risk for ARDS in those with the C allele absent       1/183
This implies that people with the C allele present are
approximately nine times as likely to develop ARDS as those
without this allele. In general, using the notation presented in
Table 2, the RR can be expressed as follows:
RR = Estimated relative risk =
Estimated risk in the exposed group 
=
a/(a + b)
Estimated risk in the unexposed group   c/(c + d)
The estimate of RR does not follow a Normal distribution.
However, an approximate 95% confidence interval for the
true population RR can be calculated by first considering the
natural logarithm (ln) of the estimated RR. The standard error
(SE) of ln RR is approximated by:
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SE(ln RR) ≅
The 95% confidence interval [2] for the population ln RR is
(ln RR – 1.96 SE [ln RR]) to (ln RR + 1.96 SE [ln RR])
For the data given in Table 1, ln RR = ln(9.19) = 2.22, and
the SE of ln RR is
SE(ln RR) ≅ = 1.040
Therefore, the 95% confidence interval for the population ln
RR is given by
2.22 – 1.96 × 1.040 to 2.22 + 1.96 × 1.040 (i.e. 0.182 to 4.258)
We need to antilog (ex) these lower and upper limits in order
to obtain the 95% confidence interval for the RR. The 95%
confidence interval for the population RR is therefore given by
the following:
e0.182 to e4.258 (i.e. 1.12 to 70.67)
Therefore, the population RR is likely to be between 1.12 and
70.67. This interval gives a very wide range of possible values
for the risk ratio. It is wide because of the small sample size
and the rarity of ARDS. However, the interval suggests that
the risk ratio is greater than 1, indicating that there is a
significantly greater risk for developing ARDS in patients with
the C allele present.
A RR equal to 1 would represent no difference in risk for the
exposed group over the unexposed group. Therefore, a
confidence interval not containing 1 within its range suggests
that there is a significant difference between the exposed and
the unexposed groups.
Odds ratio
The use of odds was introduced in Statistics review 8 [3].
The odds of an individual exposed to a risk factor developing
a disease is the ratio of the number exposed who develop the
disease to the number exposed who do not develop the
disease. For the data given in Table 1, the estimated odds of
developing ARDS if the C allele is present are 11/208 = 0.053.
The odds ratio (OR) is the ratio of the odds of the disease in
the group exposed to the factor, to the odds of the disease in
the unexposed group. For the data given in Table 1, the OR is
estimated by the following:




Estimated odds of ARDS in those with the C allele absent      1/182
This value is similar to that obtained for the RR for these data.
Generally, when the risk of the disease in the unexposed is
low, the OR approximates to the risk ratio. This applies in the
ARDS study, where the estimate of the risk for ARDS for
those with the C allele absent was 1/183 = 0.005. Therefore,
again, the OR implies that patients with the C allele present
are approximately nine times as likely to develop ARDS as
those with genotype TT. In general, using the notation given
in Table 2, the OR can be expressed as follows:
OR = Estimated odds ratio =
Estimated odds for the exposed group   
=
a/b
Estimated odds for the unexposed group     c/d
An approximate 95% confidence interval for the true
population OR can be calculated in a similar manner to that
for the RR, but the SE of ln OR is approximated by
SE(ln OR) ≅
For the data given in Table 1, ln OR = 2.26 and the SE of ln
OR is given by the following:
SE(ln ΟR) ≅ = 1.049
Therefore, the 95% confidence interval for the population ln
OR is given by
2.26 – 1.96 × 1.049 to 2.26 + 1.96 × 1.049 (i.e. 0.204 to 4.316)
Again, we need to antilog (ex) these lower and upper limits in























Number of patients according to genotype and disease
outcome
ARDS
Genotype Yes No Total
CC or CT 11 208 219
TT 1 182 183
Total 12 390 402
Presented are data on outcomes from a study conducted by Quasney
and coworkers [1] on the association between surfactant protein B





Exposed to factor  a b a + b
Unexposed to factor  c d c + d



















95% confidence interval for the population RR is given by the
following:
e0.204 to e4.316 (i.e. 1.23 to 74.89)
Therefore the population OR is likely to be between 1.23 and
74.89 – a similar confidence interval to that obtained for the
risk ratio. Again, the fact that the interval does not contain 1
indicates that there is a significant difference between the
genotype groups.
The OR has several advantages. Risk cannot be estimated
directly from a case–control study, in which patients are
selected because they have a particular disease and are
compared with a control group who do not, and therefore
RRs are not calculated for this type of study. However, the
OR can be used to give an indication of the RR, particularly
when the incidence of the disease is low. This often applies in
case–control studies because such studies are particularly
useful for rare diseases.
The OR is a symmetric ratio in that the OR for the disease
given the risk factor is the same as the OR for the risk factor
given the disease. ORs also form part of the output when
carrying out logistic regression, an important statistical
modelling technique in which the effects of one or more
factors on a binary outcome variable (e.g. survival/death) can
be examined simultaneously. Logistic regression will be
covered in a future review.
In the case of both the risk ratio and the OR, the reciprocal of
the ratio has a direct interpretation. In the example given in
Table 1, the risk ratio of 9.19 measures the increased risk of
those with the C allele having ARDS. The reciprocal of this
(1/9.19 = 0.11) is also a risk ratio but measures the reduced
risk of those without the C allele having ARDS. The reciprocal
of the odds ratio – 1/9.63 = 0.10 – is interpreted similarly.
Both the RR and the OR can also be used in the context of
clinical trials to assess the success of the treatment relative
to the control.
Attributable risk
Attributable risk (AR) is a measurement of risk that takes into
account both the RR and the prevalence of the risk factor in a
population. It can be considered to be the proportion of
cases in a population that could be prevented if the risk factor
were to be eliminated. Whereas RR is a risk ratio, AR is a risk
difference. It can be derived as follows using the notation in
Table 2.
If exposure to the risk factor were eliminated, then the risk for
developing the disease would be that of the unexposed. The
expected number of cases is then given by this risk multiplied
by the sample size (n):
Risk =
c           
Expected number = 
nc
c+d                                         c+d
The AR is the difference between the actual number of cases
in a sample and the number of cases that would be expected
if exposure to the risk factor were eliminated, expressed as a
proportion of the former. From Table 2 it can be seen that the
actual number of cases is a + c, and so the difference
between the two is the number of cases that can be directly
attributed to the presence of the risk factor. The AR is then
calculated as follows:
=                        =
overall risk – risk among the unexposed
overall risk
Where the overall risk is defined as the proportion of cases in
the total sample [4].
Consider the example of the risk of ARDS for different
genotypes given in Table 1. The overall risk for developing
ARDS is estimated by the prevalence of ARDS in the study
sample (i.e. 12/402 [0.030]). Similarly, the risk among the
unexposed (i.e. those without the C allele) is 1/183 (0.005).
This gives an AR of (0.030 – 0.005)/0.030 = 0.816,
indicating that 81.6% of ARDS cases can be directly
attributable to the presence of the C allele. This high value
would be expected because there is only one case of ARDS
among those without the C allele.
There are two equivalent formulae for AR using the
prevalence of the risk factor and the RR. They are as follows:
and
Where pE is the prevalence of the risk factor in the population
and pC is the prevalence of the risk factor among the cases.
The two prevalence measurements can then be estimated
from Table 2 as follows:
For the data in Table 1, the RR = 9.19, pE = 219/402 =
0.545, and pC = 11/12 = 0.917. Thus, both formulae give an
AR of 81.6%.
Providing the disease is rare, the second formula allows the
AR to be calculated from a case–control study in which the
prevalence of the risk factor can be obtained from the cases
and the RR can be estimated from the OR.
The approximate 95% confidence limits for attributable risk










































) u exp( ) bc ad ( nc
) u exp( bc ad
± − +
± −290
For the data given in Table 1:
= 2.288
This gives the 95% confidence interval for the population AR
as
= 0.312 to 0.978
This indicates that the population AR is likely to be between
31.2% and 97.8%.
Risk measurements in clinical trials
Risk measurements can also be calculated from the results of
clinical trials where the outcome is dichotomous. For
example, in the study into early goal-directed therapy in the
treatment of severe sepsis and septic shock by Rivers and
coworkers [5], one of the outcomes measured was in-
hospital mortality. Of the 263 patients who were randomly
allocated to either early goal-directed therapy or standard
therapy, 236 completed the therapy period with the
outcomes shown in Table 3.
The RR is calculated as above, but in this situation exposure
to the factor is considered to be exposure to the treatment,
and the presence of the disease is replaced with success in
the outcome (survived), giving the following:
RR =             = 1.34
This indicates that the chance for those who undergo early
goal-directed therapy having a successful outcome is 1.34
times as high as for those who undergo the standard therapy.
The OR is obtained in a similar manner, giving the following:
OR =             = 2.04
This indicates that the odds of survival for the recipients of
early goal-directed therapy are twice those of the recipients
of the standard therapy. Because this is not a rare outcome,
the RR and the OR are not particularly close, and in this case
the OR should not be interpreted as a risk ratio. Both
methods of assessing increased risk are viable in this type of
study, but RR is generally easier to interpret.
The AR indicates that 14.4% of the successful outcomes can




Another useful measurement of success in a clinical trial is the
difference between the proportion of adverse events in the
control group and the intervention group. This difference is
referred to as the absolute risk reduction (ARR). Therefore, for
the data given in Table 3, the proportion of adverse outcomes
in the control group is 59/119 (0.496) and that in the
intervention group is 38/117 (0.325), giving an ARR of 0.496 –
0.325 = 0.171. This indicates that the success rate of the
therapy is 17.1% higher than that of the standard therapy.
Because the ARR is the difference between two proportions,
its confidence interval can be calculated as shown in
Statistics review 8 [3].
For the data given in Table 3 the SE is calculated as 0.0634,
giving a 95% confidence interval of 0.047 to 0.295. This
indicates that the population ARR is likely to be between
4.7% and 29.5%.
Number needed to treat
The number needed to treat (NNT) is also a measurement of
the effectiveness of a treatment when the outcome is
dichotomous. It estimates the number of patients who would
need to be treated in order to obtain one more success than
that obtained with a control treatment. This could equally well
be described as the number that would need to be treated in
order to prevent one additional adverse outcome as
compared with the control treatment. This definition indicates
its relationship with the ARR, of which it is the reciprocal.
For the data given in Table 3 the NNT value is 1/0.171 = 5.8,
indicating that the intervention achieved one more success
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Table 3
Outcomes of the study conducted by Rivers and coworkers
Outcome
Therapy Survived Died Total
Early goal-directed 79 38 117
Standard 60 59 119
Total 139 97 236
Presented are data on outcomes from the study conducted by Rivers
























for every six patients receiving the early goal-directed therapy
as compared with the standard therapy.
In an intervention the NNT would be expected to be small; the
smaller the NNT, the more successful the intervention. At the
other end of the scale, if the treatment had no effect then the
NNT would be infinitely large because there would be zero
risk reduction in its use.
In prophylaxis the difference between the control and
intervention proportions could be very small, which would
result in the NNT being quite high, but the prophylaxis could
still be considered successful. For example, the NNT for use
of aspirin to prevent death 5 weeks after myocardial infarction
is quoted as 40, but it is still regarded a successful
preventive measure.
Number needed to harm
A negative NNT value indicates that the intervention has a
higher proportion of adverse outcomes than the control
treatment; in fact it is causing harm. It is then referred to as
the number needed to harm (NNH). It is a useful
measurement when assessing the relative benefits of a
treatment with known side effects. The NNT of the treatment
can be compared with the NNH of the side effects.
As the NNT is the reciprocal of the ARR, the confidence
interval can be obtained by taking the reciprocal of the
confidence limits of the ARR. For the data given in Table 3
the 95% confidence interval for the ARR is 0.047 to 0.295,
giving a 95% confidence interval for NNT as 3.4 to 21.3. This
indicates that the population NNT is likely to lie between 3.4
and 21.3.
Although the interpretation is straightforward in this example,
problems arise when the confidence interval includes zero,
which is not a possible value for the NNT. Because the
difference in the proportions may be quite small, this should
result in a large NNT, which is clearly not the case. In this
situation the confidence interval is not the set of values
between the limits but the values outside of the limits [6]. For
example, if the confidence limits were calculated as –15 to
+3, then the confidence interval would be the values from —∞
to –15 and 3 to +∞.
Limitations
The use of the term ‘attributable risk’ is not consistent. The
definition used in this review is the one given in the cited
references, but care must be taken in interpreting published
results because alternative definitions might have been
used.
Care should be taken in the interpretation of an OR. It may
not be appropriate to regard it as approximating to a RR.
Consideration needs to be given to the type of study carried
out and the incidence of the disease.
Conclusion
RR and OR can be used to assess the association between a
risk factor and a disease, or between a treatment and its
success. Attributable risk measures the impact of exposure to
a risk factor. ARR and NNT provide methods of measuring
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